These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

125 related items for PubMed ID: 7509370

  • 1. Zidovudine treatment results in the selection of human immunodeficiency virus type 1 variants whose genotypes confer increasing levels of drug resistance.
    Kellam P, Boucher CA, Tijnagel JM, Larder BA.
    J Gen Virol; 1994 Feb; 75 ( Pt 2)():341-51. PubMed ID: 7509370
    [Abstract] [Full Text] [Related]

  • 2. Retroviral recombination can lead to linkage of reverse transcriptase mutations that confer increased zidovudine resistance.
    Kellam P, Larder BA.
    J Virol; 1995 Feb; 69(2):669-74. PubMed ID: 7529334
    [Abstract] [Full Text] [Related]

  • 3. Fifth mutation in human immunodeficiency virus type 1 reverse transcriptase contributes to the development of high-level resistance to zidovudine.
    Kellam P, Boucher CA, Larder BA.
    Proc Natl Acad Sci U S A; 1992 Mar 01; 89(5):1934-8. PubMed ID: 1371886
    [Abstract] [Full Text] [Related]

  • 4. Transmitted human immunodeficiency virus type 1 carrying the D67N or K219Q/E mutation evolves rapidly to zidovudine resistance in vitro and shows a high replicative fitness in the presence of zidovudine.
    García-Lerma JG, MacInnes H, Bennett D, Weinstock H, Heneine W.
    J Virol; 2004 Jul 01; 78(14):7545-52. PubMed ID: 15220429
    [Abstract] [Full Text] [Related]

  • 5. Sequence analysis of reverse transcriptase genes of zidovudine (AZT)-resistant and -sensitive human immunodeficiency virus type 1 strains.
    Sheehy N, Desselberger U.
    J Gen Virol; 1993 Feb 01; 74 ( Pt 2)():223-8. PubMed ID: 7679140
    [Abstract] [Full Text] [Related]

  • 6. An in vivo mutation from leucine to tryptophan at position 210 in human immunodeficiency virus type 1 reverse transcriptase contributes to high-level resistance to 3'-azido-3'-deoxythymidine.
    Hooker DJ, Tachedjian G, Solomon AE, Gurusinghe AD, Land S, Birch C, Anderson JL, Roy BM, Arnold E, Deacon NJ.
    J Virol; 1996 Nov 01; 70(11):8010-8. PubMed ID: 8892925
    [Abstract] [Full Text] [Related]

  • 7. Identification of novel mutations that confer drug resistance in the human immunodeficiency virus polymerase gene.
    Gu Z, Gao Q, Fang H, Parniak MA, Brenner BG, Wainberg MA.
    Leukemia; 1994 Apr 01; 8 Suppl 1():S166-9. PubMed ID: 7512178
    [Abstract] [Full Text] [Related]

  • 8. Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT).
    Larder BA, Kemp SD.
    Science; 1989 Dec 01; 246(4934):1155-8. PubMed ID: 2479983
    [Abstract] [Full Text] [Related]

  • 9. Use of evolutionary limitations of HIV-1 multidrug resistance to optimize therapy.
    Chow YK, Hirsch MS, Merrill DP, Bechtel LJ, Eron JJ, Kaplan JC, D'Aquila RT.
    Nature; 1993 Feb 18; 361(6413):650-4. PubMed ID: 7679778
    [Abstract] [Full Text] [Related]

  • 10. Variations in reverse transcriptase and RNase H domain mutations in human immunodeficiency virus type 1 clinical isolates are associated with divergent phenotypic resistance to zidovudine.
    Ntemgwa M, Wainberg MA, Oliveira M, Moisi D, Lalonde R, Micheli V, Brenner BG.
    Antimicrob Agents Chemother; 2007 Nov 18; 51(11):3861-9. PubMed ID: 17724152
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Characterization of HIV isolates arising after prolonged zidovudine therapy.
    Mayers DL, McCutchan FE, Sanders-Buell EE, Merritt LI, Dilworth S, Fowler AK, Marks CA, Ruiz NM, Richman DD, Roberts CR.
    J Acquir Immune Defic Syndr (1988); 1992 Nov 18; 5(8):749-59. PubMed ID: 1381438
    [Abstract] [Full Text] [Related]

  • 16. Reverse transcriptase sequence of paired isolates of cerebrospinal fluid and blood from patients infected with human immunodeficiency virus type 1 during zidovudine treatment.
    Di Stefano M, Sabri F, Leitner T, Svennerholm B, Hagberg L, Norkrans G, Chiodi F.
    J Clin Microbiol; 1995 Feb 18; 33(2):352-5. PubMed ID: 7536214
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Mutational patterns associated with the 69 insertion complex in multi-drug-resistant HIV-1 reverse transcriptase that confer increased excision activity and high-level resistance to zidovudine.
    Cases-González CE, Franco S, Martínez MA, Menéndez-Arias L.
    J Mol Biol; 2007 Jan 12; 365(2):298-309. PubMed ID: 17070543
    [Abstract] [Full Text] [Related]

  • 19. Host-parasite dynamics and outgrowth of virus containing a single K70R amino acid change in reverse transcriptase are responsible for the loss of human immunodeficiency virus type 1 RNA load suppression by zidovudine.
    de Jong MD, Veenstra J, Stilianakis NI, Schuurman R, Lange JM, de Boer RJ, Boucher CA.
    Proc Natl Acad Sci U S A; 1996 May 28; 93(11):5501-6. PubMed ID: 8643604
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.